Join our daily newsletter At The Bell to receive exclusive market insights
- Actinogen Medical (ACW) is clear to enrol first patients into its Alzheimer’s Disease treatment clinical trial after receiving ethics committee approval
- ACW is now able to commence the first stage of its two-part XanaMIA studies, which will study improvements in cognitive ability in patients and volunteers with the first clinical stage of Alzheimers
- The first stage of the study — XanaMIA Part A — will include 100 healthy patients to confirm the maximum effective dose of its proposed treatment candidate, Xanamem
- From there, XanaMIA Part B will assess the efficacy of Xanamem using the minimum effective dose conducted in a cohort of patients
- Actinogen Medical shares are up 11.9 per cent following the announcement and trading at 11.8 cents
Actinogen Medical (ACW) is clear to enrol first patients into its Alzheimer’s Disease treatment clinical trial after receiving ethics committee approval.
The clinical-stage biotechnology company received approval from the Bellberry Human Research Ethics Committee meaning it can commence the first stage of its XanaMIA study.
Broadly, the two-part study is designed to study improvements in cognitive ability in older volunteers, and patients with Mild Cognitive Impairment (MCI), the first clinical stage of Alzheimers, with the first patients set to enrol in July.
The first stage of the study — XanaMIA Part A — will include 100 healthy patients and be conducted across four clinics in Australia in a dose-ranging study of five milligram and 10 milligram Xanamem doses, to confirm the minimum effective dose.
According to ACW, Xanamem was developed in response to evidence of a strong association between chronically raised cortisol levels in the blood and in the brain and the development of cognitive impairment associated with a number of conditions and Alzheimer’s disease.
From there, XanaMIA Part B will assess the efficacy of Xanamem using the minimum effective dose conducted in a cohort of patients with Mild Cognitive Impairment due to biomarker positive, early-stage Alzheimer’s Disease.
Actinogen Medical shares are up 11.9 per cent following the announcement and trading at 11.8 cents at 11:21 am AEST.
